N4 Pharma PLC New Corporate Presentation
11 June 2024 - 8:16PM
RNS Non-Regulatory
RNS Number : 9877R
N4 Pharma PLC
11 June 2024
N4 Pharma
plc
("N4
Pharma" or the "Company")
New Corporate
Presentation
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments and vaccines, is pleased to
announce that a new Corporate Presentation has been published.
The Corporate Presentation can be
viewed on the Company's interactive investor hub, at:
https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
|
investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia
Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
InvestorHub
Engage with us by asking questions,
watching video summaries and seeing what other shareholders have to
say.
|
https://investors.n4pharma.com/link/YeNdZP
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to
partner with companies developing novel antigens in these fields to
use Nuvec® as the delivery vehicle for these antigens. As these
products progress through pre‐clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the
Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRAEAEKFFFSLEFA
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2024 to Jun 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Jun 2023 to Jun 2024
